Economic Burden of Hemophilia A

Costs associated with treating hemophilia A can present significant challenges. Factor VIII concentrates can account for more than 93% of the total cost of hemophilia care, making them the largest expense when treating hemophilia A.1 Even minimal changes in price can amount to significant disparities in annual factor VIII expenditures.2


References: 1. Smith PS, Teutsch SM, Shaffer PA, Rolka H, Evatt B. Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis. J Pediatr. 1996;129:424–431. 2. Survey on Hemophilia Care and Price Monitoring, United States, Wave #18.Orange, CT: The Marketing Research Bureau Inc.;2008.